hepatitis C

Gilead Launches HepConnect Initiative to Reduce Hepatitis C Infections in Greater Appalachia

Summary: 
  • Funding will Expand Testing, Harm Reduction Services and Healthcare Infrastructure in States with Highest Infection Rates
  • Harm Reduction Coalition Selected as Lead Grantee to Oversee 5-year Effort to Implement Proven Harm Reduction Strategies in Indiana, Kentucky, North Carolina, Tennessee and West Virginia
Press Release
  • Funding will Expand Testing, Harm Reduction Services and Healthcare Infrastructure in States with Highest Infection Rates
  • Harm Reduction Coalition Selected as Lead Grantee to Oversee 5-year Effort to Implement Proven Harm Reduction Strategies in Indiana, Kentucky, North Carolina, Tennessee and West Virginia

New Elton John AIDS Foundation Funding to Combat HIV Epidemics

Article

EJAF has announced new funding initiatives to increase advocacy and service delivery for people living with and at-risk for HIV and hepatitis C.

Funding for the new initiatives will be supported by EJAF and include financial contributions from Gilead Sciences. Gilead will also provide a donation of hepatitis C products to cure 5,000 patients – a critical contribution in a region where up to 97% of people living with HIV are co-infected with hepatitis C.

Quest Diagnostics Streamlines Hepatitis C Test Menu to Help Save Lives

Multimedia with summary

For the 3.5 million people infected with the hepatitis C virus in the United States, time is of the essence. Hepatitis C is the most common blood-borne infection in this country and, if not diagnosed and treated early enough, can cause liver damage, cirrhosis, liver cancer, and even death.

Joan’s Story: A Personal Commitment to Patients Living with Hepatitis C

Multimedia with summary

For Joan, hepatitis C is much more than a significant global public health challenge—it’s personal. It has played a role in the story of her family, and it was from her family that she learned the importance of “sticking together,” as well as the importance of the work she and her team does every day.

Our Mission: Helping Patients Prevail Over Serious Diseases

Multimedia with summary

Bristol-Myers Squibb is a global biopharmaceutical company focused on discovering, developing and delivering innovative medicines for patients with serious and life-threatening diseases. We are exploring new approaches to treat diseases with significant unmet medical need. Through the Bristol-Myers Squibb Foundation, we promote health equity and seek to improve health outcomes of populations disproportionately affected by serious diseases. Each day, our employees around the world are committed to working together for patients – it drives everything we do.

Transcription Factor May Protect Against Hepatic Injury Caused by Hepatitis C and Alcohol

More damage seen when FOXO3 suppressed, according to report in The American Journal of Pathology
Press Release

Philadelphia, PA, November 11, 2013 /3BL Media/ – New data suggest that the transcription factor FOXO3 may protect against alcohol-induced liver injury. Researchers determined that alcohol given to mice deficient in FOXO3 caused severe liver injury resembling human alcoholic hepatitis. Further they found that although hepatitis C virus (HCV) and alcohol independently activated FOXO3, in combination they suppressed FOXO3, reduced expression of cytoprotective genes, and worsened liver injury. The results are published in The American Journal of Pathology.

Harvard and MIT Students Rally Boston to Join Global Guinness World Record Attempt on World Hepatitis Day

Team HBV Chapters in Boston and Quest Diagnostics Urge City Residents and Visitors to Come Out and Be Counted at 'See No Evil, Hear No Evil, Speak No Evil' Viral Hepatitis Awareness Event, Boston Common
Press Release

(3BL Media) Boston, MA - August 1, 2012 - Students at Harvard and Massachusetts Institute of Technology aren't the type to take the summer off.

Subscribe to hepatitis C